Growth Metrics

Innoviva (INVA) Cost of Revenue (2023 - 2026)

Innoviva filings provide 5 years of Cost of Revenue readings, the most recent being $25.6 million for Q3 2025.

  • On a quarterly basis, Cost of Revenue rose 223.73% to $25.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $52.2 million, a 39.1% increase, with the full-year FY2023 number at $41.0 million, up 1549.52% from a year prior.
  • Cost of Revenue hit $25.6 million in Q3 2025 for Innoviva, up from $10.6 million in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $25.6 million in Q3 2025 to a low of $1.6 million in Q1 2023.
  • Median Cost of Revenue over the past 3 years was $9.3 million (2023), compared with a mean of $10.4 million.
  • Biggest five-year swings in Cost of Revenue: skyrocketed 585.69% in 2024 and later fell 26.43% in 2025.
  • Innoviva's Cost of Revenue stood at $10.2 million in 2023, then dropped by 22.21% to $7.9 million in 2024, then skyrocketed by 223.73% to $25.6 million in 2025.
  • The last three reported values for Cost of Revenue were $25.6 million (Q3 2025), $10.6 million (Q2 2025), and $8.1 million (Q1 2025) per Business Quant data.